Harmony Biosciences Holdings Inc
(NAS:HRMY)
$
34.2
-0.52 (-1.5%)
Market Cap: 1.95 Bil
Enterprise Value: 1.75 Bil
PE Ratio: 16.21
PB Ratio: 3.27
GF Score: 65/100 Harmony Biosciences Holdings Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Jun 10, 2021 / 07:50PM GMT
Release Date Price:
$32.64
(-0.43%)
Graig Suvannavejh
Goldman Sachs Group, Inc., Research Division - Executive Director & Senior Equity Research Analyst
Okay. Well, good afternoon, everyone. Welcome to the 3:50 p.m. session on day 3 of the 42nd Annual Goldman Sachs Global Healthcare Conference. My name is Graig Suvannavejh. I cover U.S. and European biopharma names for the firm, and it's my great pleasure to be hosting Harmony Biosciences in a fireside chat discussion today.
And joining us from the company, CEO, John Jacobs; and CFO, Sandip Kapadia. Welcome, gentlemen. It's good to see you.
John Charles Jacobs
Harmony Biosciences Holdings, Inc. - President, CEO & Director
Thank you, Graig. Same here.
Questions & Answers
Graig Suvannavejh
Goldman Sachs Group, Inc., Research Division - Executive Director & Senior Equity Research Analyst
Okay. Great. I think a great place to start is just kind of maybe, John, you telling us a little bit more about the Harmony story. A relatively new company and a new publicly traded
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot